← Back to Clinical Trials
Recruiting NCT07599930

NCT07599930 Impact of a Novel Functional Snack on Perimenopausal Symptoms and Well-being

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07599930
Status Recruiting
Phase
Sponsor King's College London
Condition Perimenopause
Study Type INTERVENTIONAL
Enrollment 20 participants
Start Date 2026-04-24
Primary Completion 2026-12

Eligibility & Interventions

Sex Female only
Min Age 40 Years
Max Age 55 Years
Study Type INTERVENTIONAL
Interventions
Functional SnacksPlacebo Snacks

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 20 participants in total. It began in 2026-04-24 with a primary completion date of 2026-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a clinical trial aimed to investigate if a novel phytochemical and fibre-rich snack can improve perimenopausal symptoms and well-being in perimenopausal women aged 40-55 and not on hormone replacement therapy. Hypothesis: The investigators hypothesise that the phytochemical and fibre-rich snack will improve perimenopausal symptoms via a gut microbiota mediated mechanism. Main research questions: Does eating the snack every day lower menopause symptoms such as hot flushes, night sweats, mood changes, and sleep problems? Does the snack improve mood, stress, anxiety, sleep, and overall quality of life? Does the snack improve the balance of bacteria in the gut, and could this be part of how it helps symptoms?

Eligibility Criteria

Inclusion Criteria: * Adults aged 40 to 55 * Score 14 or higher on the Menopause Rating Scale * For intervention purposes, eligible participants are also required to have a mobile phone and be able to read and speak English. Exclusion Criteria: * People who consume more than 15g of fibre a day * People who consume more than 2 cups of coffee or tea a day * People who consume more than 4 portions (portion = 80g) of fruits and vegetables a day * People who do not have any intolerances or allergies to the following: * Any kinds of nuts including tree nuts, peanuts, hazelnuts and coconuts * Chia seeds * Pumpkin seeds * Sunflower seeds * Dates * Gluten * Dairy * Oats * Barley * Soya * People who smoke or vape or have smoked or vaped in the last 2 years * People who consume more than 21 drinks a week or have a history of excess alcohol intake * People with comorbid conditions that may limit participation in the study, such as a history of an acute cardiovascular event, including coronary artery disease, previous myocardial infarction (heart attack), stroke, peripheral artery disease, diabetes mellitus, chronic kidney disease, metabolic syndrome, malignancies, cardiac arrhythmia, renal failure, cardiac failure, uncontrolled hypertension, cancer or major psychiatric or cognitive problems * People receiving drug treatment for lipid metabolisms (e.g., statins) * People with a history of long-term use of medicines known to influence glucose metabolism (e.g., corticosteroids) or aspirin * People taking antihypertensive drugs * People who take antibiotics or bacterial agents (Probiotics) within 1 month * People who take vitamin/dietary supplements within 1 month * Pregnant women, women ready for pregnancy, and nursing mothers * cardiac arrhythmia * renal failure * heart failure (NYHA II-IV) * diabetes mellitus * Malignant disease * People who have participated in a biomedical study within the past 3 months * Women who require hormone replacement therapy during the development of the protocol.

Contact & Investigator

Central Contact

Ana Rodriguez-Mateos, PhD

✉ ana.rodriguez-mateos@kcl.ac.uk

📞 +44 (0)20 7848 4349

Principal Investigator

Ana Rodriguez-Mateos, PhD

PRINCIPAL INVESTIGATOR

King's College London

Frequently Asked Questions

Who can join the NCT07599930 clinical trial?

This trial is open to female participants only, aged 40 Years or older, up to 55 Years, studying Perimenopause. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07599930 currently recruiting?

Yes, NCT07599930 is actively recruiting participants. Contact the research team at ana.rodriguez-mateos@kcl.ac.uk for enrollment information.

Where is the NCT07599930 trial being conducted?

This trial is being conducted at London, United Kingdom.

Who is sponsoring the NCT07599930 clinical trial?

NCT07599930 is sponsored by King's College London. The principal investigator is Ana Rodriguez-Mateos, PhD at King's College London. The trial plans to enroll 20 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology